Literature DB >> 11352792

Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons.

C L Deal1.   

Abstract

Measurement of bone density is crucial for evaluating fracture risk. Low bone mass is a powerful predictor of fracture and is necessary to assess the need for treatment. Dual energy x-ray absorptiometry is accurate and precise. Use of bone density for monitoring therapy is an important tool for evaluating response to therapy, but an understanding of the limitations of the procedure are important for the practicing physician. Precision error of the technology and what change in density is clinically significant (least significant change) are important concepts to interpret results and make appropriate treatment decisions. This article reviews the use of bone densitometry as a tool for monitoring treatment in patients with low bone mass.

Entities:  

Mesh:

Year:  2001        PMID: 11352792     DOI: 10.1007/s11926-001-0023-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  22 in total

1.  Monitoring skeletal changes by radiological techniques.

Authors:  C C Glüer
Journal:  J Bone Miner Res       Date:  1999-11       Impact factor: 6.741

Review 2.  Bone densitometry: the best way to detect osteoporosis and to monitor therapy.

Authors:  P D Miller; C Zapalowski; C A Kulak; J P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

Review 3.  Bone matters: are density increases necessary to reduce fracture risk?

Authors:  K G Faulkner
Journal:  J Bone Miner Res       Date:  2000-02       Impact factor: 6.741

Review 4.  Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.

Authors:  M R McClung
Journal:  Bone       Date:  1996-11       Impact factor: 4.398

5.  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

6.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

7.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

8.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

9.  Baseline measurement of bone mass predicts fracture in white women.

Authors:  S L Hui; C W Slemenda; C C Johnston
Journal:  Ann Intern Med       Date:  1989-09-01       Impact factor: 25.391

10.  The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements?

Authors:  P D Miller; S L Bonnick; C C Johnston; M Kleerekoper; R L Lindsay; L M Sherwood; E S Siris
Journal:  J Clin Densitom       Date:  1998       Impact factor: 2.963

View more
  1 in total

Review 1.  Bone mineral density in people living with HIV: a narrative review of the literature.

Authors:  M J Kruger; T A Nell
Journal:  AIDS Res Ther       Date:  2017-07-26       Impact factor: 2.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.